BioCryst Pharmaceuticals BCRX Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's proceeds from exercises of stock options and other stock issuances?
- BioCryst Pharmaceuticals (BCRX) reported proceeds from exercises of stock options and other stock issuances of $19.48M in Q1 2026.
- How has BioCryst Pharmaceuticals's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- BioCryst Pharmaceuticals's proceeds from exercises of stock options and other stock issuances increased by 715.0% year-over-year, from $2.39M to $19.48M.
- What is the long-term trend for BioCryst Pharmaceuticals's proceeds from exercises of stock options and other stock issuances?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's proceeds from exercises of stock options and other stock issuances has grown at a -16.6% compound annual growth rate (CAGR), from $15.73M to $9.12M.